BACKGROUND: It has been suggested that the prevalence of microsatellite instability (MSI) is high in intramucosal differentiated gastric cancers with gastric foveolar phenotypic expression, and that these tumors are prone to lose their glandular structures and progress to undifferentiated-type lesions. To test this hypothesis, we examined the relationships among human MutL homologue 1 (hMLH1) expression (which is linked to MSI), the phenotype, and the histological type in patients with advanced and intramucosal gastric cancer. METHODS: We analyzed hMLH1 expression by immunohistochemistry in 70 advanced and 30 intramucosal gastric cancers with histological evaluation and assessment of the phenotype, and Cdx2 expression determined by immunohistochemistry. The MSI status was also examined in 20 cases. RESULTS: Thirteen (18.6%) advanced and 5 (16.7%) intramucosal gastric cancers were judged to be hMLH1-negative. In the advanced cases, no association was observed between the histological type and the phenotype and loss of hMLH1. In the intramucosal cases, MUC5AC expression was observed in all 5 hMLH1-negative differentiated-type cancers. However, no hMLH1-negative lesions were detected in the intramucosal undifferentiated cancers (0/14; P < 0.05 vs differentiated types). In the advanced cases, MSI-positivity (MSI +) and loss of hMLH1 expression did correlate (P < 0.0001), while no association was observed between MSI +, histological type, and phenotype. CONCLUSION: Our data support the hypothesis that, phenotypically, some MSI-positive differentiated gastric cancers of gastric foveolar phenotypic expression may easily change, from gastric to intestinal phenotypic expression, also changing, histologically, from differentiated to undifferentiated type with progression.
BACKGROUND: It has been suggested that the prevalence of microsatellite instability (MSI) is high in intramucosal differentiated gastric cancers with gastric foveolar phenotypic expression, and that these tumors are prone to lose their glandular structures and progress to undifferentiated-type lesions. To test this hypothesis, we examined the relationships among human MutL homologue 1 (hMLH1) expression (which is linked to MSI), the phenotype, and the histological type in patients with advanced and intramucosal gastric cancer. METHODS: We analyzed hMLH1 expression by immunohistochemistry in 70 advanced and 30 intramucosal gastric cancers with histological evaluation and assessment of the phenotype, and Cdx2 expression determined by immunohistochemistry. The MSI status was also examined in 20 cases. RESULTS: Thirteen (18.6%) advanced and 5 (16.7%) intramucosal gastric cancers were judged to be hMLH1-negative. In the advanced cases, no association was observed between the histological type and the phenotype and loss of hMLH1. In the intramucosal cases, MUC5AC expression was observed in all 5 hMLH1-negative differentiated-type cancers. However, no hMLH1-negative lesions were detected in the intramucosal undifferentiated cancers (0/14; P < 0.05 vs differentiated types). In the advanced cases, MSI-positivity (MSI +) and loss of hMLH1 expression did correlate (P < 0.0001), while no association was observed between MSI +, histological type, and phenotype. CONCLUSION: Our data support the hypothesis that, phenotypically, some MSI-positive differentiated gastric cancers of gastric foveolar phenotypic expression may easily change, from gastric to intestinal phenotypic expression, also changing, histologically, from differentiated to undifferentiated type with progression.
Authors: T Yamachika; K Inada; Y Fujimitsu; S Nakamura; Y Yamamura; T Kitou; S H Itzkowitz; J L Werther; K Miki; M Tatematsu Journal: Virchows Arch Date: 1997-08 Impact factor: 4.064
Authors: T Hinoi; M Tani; P C Lucas; K Caca; R L Dunn; E Macri; M Loda; H D Appelman; K R Cho; E R Fearon Journal: Am J Pathol Date: 2001-12 Impact factor: 4.307
Authors: Z Jin; G Tamura; M Satoh; T Meguro; T Miura; M Hayashi; M Osakabe; K Ohmura; S Ogata; Y Endoh; T Motoyama Journal: Pathol Int Date: 2001-06 Impact factor: 2.534
Authors: A S Fleisher; M Esteller; S Wang; G Tamura; H Suzuki; J Yin; T T Zou; J M Abraham; D Kong; K N Smolinski; Y Q Shi; M G Rhyu; S M Powell; S P James; K T Wilson; J G Herman; S J Meltzer Journal: Cancer Res Date: 1999-03-01 Impact factor: 12.701
Authors: T Tsukamoto; T Mizoshita; M Mihara; H Tanaka; Y Takenaka; Y Yamamura; S Nakamura; T Ushijima; M Tatematsu Journal: Histopathology Date: 2005-06 Impact factor: 5.087
Authors: Jiwon Koh; Keun-Wook Lee; Soo Kyung Nam; An Na Seo; Ji-Won Kim; Jin Won Kim; Do Joong Park; Hyung-Ho Kim; Woo Ho Kim; Hye Seung Lee Journal: Oncologist Date: 2019-08-01
Authors: Marisa C Alvarez; Juliana C Santos; Nathália Maniezzo; Marcelo S Ladeira; Artur L C da Silva; Isabel C A Scaletsky; José Pedrazzoli; Marcelo L Ribeiro Journal: World J Gastroenterol Date: 2013-05-28 Impact factor: 5.742